Table 5.
Pharmacokinetics properties of the ‘lead hit compounds’ determined using Swiss ADME server.
| Compounds | GI absorption | BBB permeant | P-gp substrate | Skin permeation (Log Kp) (cm/s) | CYP1A2 inhibitor | CYP2C19 inhibitor | CYP2C9 inhibitor | CYP2D6 inhibitor | CYP3A4 inhibitor |
|---|---|---|---|---|---|---|---|---|---|
| Buddlenol-A | Low | No | Yes | -8.31 | No | No | No | No | No |
| Citrusin-B | Low | No | Yes | -10.03 | No | No | No | No | No |
| 9-Hydroxycanthin-6-one | High | Yes | No | -7.75 | Yes | No | No | No | No |
| Bruceolline-B | Low | No | Yes | -10.9 | No | No | No | No | No |
| Prosopine | High | Yes | No | -5.32 | No | No | No | Yes | No |
| Fisetinidol | High | No | Yes | -7.46 | No | No | No | No | No |
| Picrasidine-X | High | No | No | -7.05 | No | No | No | No | No |